Viz

What Viz does

Viz.ai, Inc. is a San Francisco-based, privately held healthcare AI company founded in 2016 that builds an enterprise AI-powered care coordination platform deployed across 2,000 U.S. hospitals covering approximately two-thirds of the U.S. population. The platform, branded Viz.ai One, integrates more than 50 FDA-cleared AI algorithms across neurological (Viz LVO, ICH, Aneurysm, SDH, CTP), vascular (PE, aortic disease), cardiac (HCM, ACS, cardiac amyloidosis), pulmonary (COPD, lung nodules, PE), radiology, and trauma workflows, with multimodal capabilities spanning imaging AI, ambient listening, NLP, and EHR-integrated generative AI through Viz Assist and Viz Agent Studio. The platform operates PACS-independently and integrates with Epic and eClinicalWorks via HL7 FHIR, enabling cross-hospital communication and specialist notification that isolated PACS-based algorithms cannot replicate.

The company monetizes primarily through quote-based enterprise SaaS subscriptions sold to hospitals, integrated delivery networks, and academic medical centers on multi-year contracts, and through a growing life sciences business involving strategic collaborations with 11 biopharma and medtech companies (Bristol Myers Squibb, Novartis, Sanofi, Regeneron, Alnylam, Johnson & Johnson) for AI-powered care pathway development, clinical trial enrollment, and real-world evidence generation. Distribution combines direct enterprise sales with channel partnerships — notably co-marketing with Johnson & Johnson, integration with Salesforce Agentforce for Health and Microsoft Cloud for Healthcare, and a European joint go-to-market with Medtronic. Viz.ai reached profitability in its healthcare segment in 2025 while doubling its life sciences business, and operates from wholly owned subsidiaries in the U.S. (HQ), the Netherlands, the United Kingdom, and Israel (engineering), holding SOC 2 Type 2, ISO 27001, ISO 27701, and ISO/IEC 42001 certifications alongside HIPAA, GDPR, and CCPA compliance.

Name

Viz

Legal name

Viz.ai, Inc.

Website

https://viz.ai

Company type

Private

Founded year

2016

Operating status

Operating

Headcount range

251–500 employees

Short description

Viz.ai provides an enterprise AI-powered care coordination platform with 50+ FDA-cleared medical imaging algorithms deployed across 2,000 U.S. hospitals. It serves hospitals, health systems, and life sciences companies with multimodal AI spanning neuro, vascular, cardio, pulmonary, and trauma workflows.

Ownership category

akta.pro rank

Product category

Healthcare AI Care Coordination Software

NAICS

Computer Systems Design Services (541512)

SIC

Services-Computer Integrated Systems Design (7373)

akta.pro primary industry

AI Orchestration & Imaging Analytics Platforms (Model Management/Triage) (HLACALAG)

akta.pro secondary industry

Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)

Keywords

• AI care coordination
• Medical imaging analysis
• Clinical decision support
• Stroke detection software
• Radiology workflow automation

Headquarters

HQ city

San Francisco

HQ country

United States

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Healthcare Subscription (Viz.ai One platform): Recurring SaaS subscriptions from hospitals and health systems for the Viz.ai One platform including Viz Neuro Suite, Viz Cardio Suite, Viz Vascular Suite, Viz Trauma Suite, Viz Radiology Suite, Viz Pulmonary Suite, Viz Assist, and Viz Agent Studio. Deployed in 2,000 U.S. hospitals. Achieved profitability in healthcare segment in 2025.
2. Life Sciences Partnerships: Strategic collaborations with 11 biopharma and medtech companies (Bristol Myers Squibb, Novartis, Sanofi, Regeneron, Alnylam, etc.) for AI-powered care pathway development, clinical trial optimization, and real-world evidence generation. Life sciences business doubled in 2025 with six new partnerships.
3. Strategic Commercialization Co-Marketing: Commercialization collaborations with medtech companies (e.g., Johnson & Johnson) to co-market AI solutions alongside their therapeutic products, generating revenue through joint go-to-market activities.

Pricing tiers

Go-to-market motion4 records

Distribution channels6 records

Marketing channels10 records

Core offering

Viz.ai operates an enterprise AI-powered care coordination platform (Viz.ai One) that integrates more than 50 FDA-cleared AI algorithms to analyze medical imaging (CT, CTA, MRI, ECG, echocardiogram) and structured clinical data, detect time-critical conditions such as stroke, hemorrhage, pulmonary embolism, aortic disease, and hypertrophic cardiomyopathy, and automatically notify specialists and coordinate care teams across hospital systems. The platform layers in Viz Assist (ambient listening and generative AI workflow assistant), Viz Agent Studio (an enterprise AI agent development platform), and disease-specific suites (Neuro, Vascular, Cardio, Pulmonary, Radiology, Trauma, Oncology) to support care coordination, clinical documentation, and custom AI pathway development.

Product overview

Viz.ai operates as a platform-plus-modules architecture: Viz.ai One is the unifying enterprise AI platform that connects imaging, EHR, and care coordination workflows across the health system, while Viz Assist (an ambient, generative-AI workflow assistant) and Viz Agent Studio (an enterprise agent-building platform) sit on top as cross-cutting AI layers. Beneath the platform, Viz.ai organizes its clinical algorithms into specialty suites — Viz Neuro Suite (including Viz LVO, Viz ICH, Viz CTP, Viz Aneurysm / Viz ANX, Viz SDH, and Viz RV/LV), Viz Vascular Suite (including Viz PE & AD / CINA CHEST), Viz Cardio Suite (including Viz HCM), Viz Pulmonary Suite, Viz Radiology Suite, Viz Trauma Suite, and Viz Oncology Suite — each providing FDA-cleared disease detection and triage modules. Viz.ai Life Sciences extends the same core infrastructure into pharmaceutical and clinical research. The suites integrate with EHR systems (Epic, eClinicalWorks) via FHIR and partner ecosystems including Microsoft Cloud for Healthcare and Salesforce Agentforce for Health.

Differentiator

Problem solved

Functional benefit

Brands

• Viz.ai One: Enterprise AI-powered care coordination platform unifying detection, workflow, and operational impact across therapeutic areas.
• Viz Assist
• Viz Neuro Suite
• Viz Cardio Suite
• Viz Vascular Suite
• Viz Pulmonary Suite
• Viz Radiology Suite
• Viz Trauma Suite
• Viz Oncology Suite
• Viz Life Sciences
• Viz Agent Studio

Products and services

• Viz.ai One
• Viz Assist
• Viz Agent Studio
• Viz Neuro Suite
• Viz Vascular Suite
• Viz Cardio Suite
• Viz Pulmonary Suite
• Viz Radiology Suite
• Viz Trauma Suite
• Viz Oncology Suite
• Viz.ai Life Sciences

Quantifiable outcome

• Reduced interfacility stroke transfer DIDO time by 44% (from 202 to 113 minutes), exceeding Joint Commission's 120-minute national benchmark by nearly 6%.
• +10 more outcomes

Named customers10 records

Segments4 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

Yes

API docs

API detail

Core technology

AI maturity

App detail

Integration9 records

AI capability14 records

Feature13 records

Partnerships

Twelve partnerships are on record, tiered core, flagship and minor.

• National Rural Health Association (NRHA)coreGTM or Marketing Partner · 30 April 2026Collaboration through NRHA's Rural Hospital & Clinic Partnership Program to help rural hospitals implement Viz.ai's AI-powered detection and care coordination tools. Includes educational webinars, case studies from peer hospitals, and engagement at NRHA's national conference. Addresses the 25% gap in rural hospital AI adoption. Viz.ai is currently deployed in 2,000 hospitals nationwide with stroke, PE, and aortic disease detection capabilities.
• Johnson & JohnsonflagshipStrategic or Co-development Partner · 23 April 2026Strategic commercialization collaboration announced April 23, 2026, to expand access to Viz.ai's FDA 510(k)-cleared AI-powered Subdural Hemorrhage software solution across U.S. hospitals. The solution provides automated detection, labeling, and quantification of subdural collections, integrated with Viz Assist for AI-driven chart summarization. The collaboration aims to identify chronic subdural hematoma patients earlier and coordinate multidisciplinary care, including identifying candidates for middle meningeal artery embolization (MMA) treatment, and is expected to drive uptake of J&J's FDA-approved TRUFILL n-BCA Liquid Embolic System.
• Alnylam PharmaceuticalsflagshipStrategic or Co-development Partner · 24 March 2026Strategic collaboration to develop an AI-enabled care pathway for earlier detection and improved care coordination of cardiac amyloidosis (ATTR-CM). The Viz Cardiac Amyloidosis Care Pathway combines Viz.ai's FDA-cleared Us2.ai echocardiography AI algorithm with generative AI and EHR connectivity, launching with a multi-site pilot study at five pilot U.S. health systems. Viz.ai's Alnylam partnership also supports the AWARE implementation study.
• SalesforceflagshipTechnology or Integration · 5 March 2026Partnership to expand Salesforce's Agentforce for Health platform with six new AI agents powered by Viz.ai, automating administrative and clinical workflows across healthcare organizations including patient referrals, electronic health record updates, hospital logistics management, and infectious disease monitoring. Early adopter MIMIT Health reported 459% ROI and $1.5M in savings. Some tools (referral triage, root cause analysis) rolling out in June 2026. Separately, Viz.ai and Salesforce also partnered to transform pharma engagement with real-time clinical intelligence for Agentforce (January 2026).
• Bristol Myers SquibbcoreStrategic or Co-development Partner · 14 August 2025Multi-year collaboration to develop AI-powered care pathway solutions including Viz HCM for hypertrophic cardiomyopathy detection. Real-world deployment of Viz HCM under the partnership has identified at least 11 new HCM diagnoses, with 63 previously undiagnosed HCM cases detected over eight months, reducing average diagnosis time from years to 37 days.
• NovartiscoreStrategic or Co-development Partner · 14 August 2025One of 11 biopharma and medtech companies partnering with Viz.ai to develop AI-powered care pathway solutions. Part of Viz.ai's life sciences business which doubled in 2025 with six new partnerships.
• SanoficoreStrategic or Co-development Partner · 14 August 2025Biopharma partner collaborating with Viz.ai on AI-powered care pathway solutions across conditions ranging from oncology to cardiovascular diseases. Referenced as a life sciences partner in Viz.ai's blog on bridging AI-powered HCP solutions.
• RegeneroncoreStrategic or Co-development Partner · 14 August 2025Biopharma partner of Viz.ai developing AI-powered care pathway solutions. Referenced in Viz.ai's article on lung disease management as an example of AI partnerships expanding chronic lung disease care.
• IMVARIAminorStrategic or Co-development PartnerReferenced as an example of a Viz.ai AI partnership expanding chronic lung disease care, alongside Sanofi and Regeneron.
• MicrosoftcoreTechnology or IntegrationViz.ai integrates with Microsoft Cloud for Healthcare, enabling health systems to access Viz.ai's AI algorithms within the Microsoft Cloud for Healthcare environment. The partnership supports the joint offering "Viz.ai and Microsoft Cloud for Healthcare."
• MedtroniccoreGTM or Marketing PartnerViz.ai Netherlands BV and Viz.ai Group have partnered with Medtronic International Trading Sarl (Medtronic Europe) to undertake joint sales, marketing, and business development activities in Europe. Each organization has separate privacy policies.
• Us2.aicoreTechnology or IntegrationViz.ai's FDA-cleared Us2.ai echocardiography AI algorithm is integrated into the Viz Cardiac Amyloidosis Care Pathway. Us2.ai's algorithm analyzes echocardiograms and, combined with generative AI and EHR connectivity, supports earlier identification of cardiac amyloidosis patients and guides clinicians through guideline-based diagnostic steps.

Scale indicators11 records

Recent moves7 records

Expansion highlights8 records

Market position

Weaknesses4 records

Competitive moat6 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/viz_ai
• Facebookfacebook.com/viz.ai.stroke

Compliance9 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds9 records

Investors19 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Viz